Symbols / ELOX $0.00 -98.38% Eloxx Pharmaceuticals, Inc.
ELOX Chart
Stock Fundamentals
|
|
|
|
|
|
About
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-07-11 | main | Oppenheimer | Outperform → Outperform | $55 |
| 2023-04-06 | reit | Oppenheimer | — → Outperform | $50 |
- Net debt of Eloxx Pharmaceuticals Inc. – NASDAQ:ELOX - TradingView Wed, 13 May 2026 07
- Eloxx Pharmaceuticals (ELOX) grants 395,680 stock options to director - Stock Titan Fri, 08 May 2026 20
- Eloxx Pharmaceuticals (ELOX) CEO boosts share ownership via option awards - Stock Titan Fri, 08 May 2026 20
- ELOX SEC Filings - Eloxx Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan hu, 07 May 2026 08
- Eloxx Pharmaceuticals (ELOX) approves 20M-plan boost, 1:2–1:20 reverse split option - Stock Titan Fri, 08 May 2026 20
- Eloxx Pharmaceuticals (ELOX) seeks Nasdaq return amid cash needs and S-1 stock sale - Stock Titan hu, 07 May 2026 20
- Coastlands Capital lists large Eloxx (ELOX) stock and pre-funded warrant stake - Stock Titan Fri, 01 May 2026 07
- Domicilium Real Estate Fund III (NASDAQ: ELOX) reports large pre-funded warrant stake - Stock Titan Mon, 04 May 2026 22
- Majority of Eloxx Pharmaceuticals (OTC: ELOX) holders back actions - Stock Titan Fri, 01 May 2026 07
- ELOX SEC Filings - Eloxx Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan Fri, 01 May 2026 07
- Coastlands stake in Eloxx Pharmaceuticals (NASDAQ: ELOX) — 1.25M shares, 16.51% - Stock Titan Fri, 01 May 2026 07
- Domicilium group (NASDAQ: ELOX) reports combined 18.6% holding in Eloxx - Stock Titan Mon, 04 May 2026 22
- Wider loss and going concern warning at Eloxx (OTC: ELOX) as cash stays tight - Stock Titan ue, 05 May 2026 10
- Eloxx Shareholders Approve Reverse Split and Equity Changes - The Globe and Mail Sat, 02 May 2026 21
- Eloxx Pharmaceuticals, Inc. has filed an IPO in the amount of $50 million. - marketscreener.com hu, 07 May 2026 04
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
6.36
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
-100.00%
|
6.36
|
0.00
|
0.00
|
| Operating Expense |
|
6.44
-27.06%
|
8.83
-48.94%
|
17.29
-49.77%
|
34.42
|
| Research And Development |
|
3.06
-14.57%
|
3.58
-58.40%
|
8.60
-63.76%
|
23.73
|
| Selling General And Administration |
|
3.38
-35.58%
|
5.25
-39.59%
|
8.69
-18.72%
|
10.69
|
| General And Administrative Expense |
|
3.38
-35.58%
|
5.25
-39.59%
|
8.69
-18.72%
|
10.69
|
| Other Gand A |
|
3.38
-35.58%
|
5.25
-39.59%
|
8.69
-18.72%
|
10.69
|
| Total Expenses |
|
6.44
-27.06%
|
8.83
-48.94%
|
17.29
-49.77%
|
34.42
|
| Operating Income |
|
-6.44
-160.86%
|
-2.47
+85.72%
|
-17.29
+49.77%
|
-34.42
|
| EBITDA |
|
-4.95
-169.54%
|
-1.83
+87.84%
|
-15.09
+54.84%
|
-33.42
|
| Normalized EBITDA |
|
-6.28
-182.28%
|
-2.22
+86.51%
|
-16.49
+50.59%
|
-33.37
|
| Reconciled Depreciation |
|
0.00
-100.00%
|
0.16
-79.73%
|
0.81
+16.40%
|
0.69
|
| EBIT |
|
-4.95
-147.42%
|
-2.00
+87.43%
|
-15.90
+53.39%
|
-34.12
|
| Total Unusual Items |
|
1.33
+242.42%
|
0.39
-72.11%
|
1.40
+3006.25%
|
-0.05
|
| Total Unusual Items Excluding Goodwill |
|
1.33
+242.42%
|
0.39
-72.11%
|
1.40
+3006.25%
|
-0.05
|
| Special Income Charges |
|
1.24
+9415.38%
|
0.01
+108.78%
|
-0.15
|
0.00
|
| Other Special Charges |
|
-1.24
-5044.00%
|
0.03
-94.27%
|
0.44
|
—
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Pretax Income |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Net Non Operating Interest Income Expense |
|
-0.86
+22.83%
|
-1.12
-24.25%
|
-0.90
+46.33%
|
-1.68
|
| Interest Expense Non Operating |
|
1.05
-8.30%
|
1.14
-0.61%
|
1.15
-40.94%
|
1.95
|
| Net Interest Income |
|
-0.86
+22.83%
|
-1.12
-24.25%
|
-0.90
+46.33%
|
-1.68
|
| Interest Expense |
|
1.05
-8.30%
|
1.14
-0.61%
|
1.15
-40.94%
|
1.95
|
| Interest Income Non Operating |
|
0.03
+22.22%
|
0.03
-89.29%
|
0.25
-8.03%
|
0.27
|
| Interest Income |
|
0.03
+22.22%
|
0.03
-89.29%
|
0.25
-8.03%
|
0.27
|
| Other Income Expense |
|
1.30
+195.25%
|
0.44
-60.99%
|
1.13
+3806.90%
|
0.03
|
| Other Non Operating Income Expenses |
|
-0.03
-150.94%
|
0.05
+120.23%
|
-0.26
-440.26%
|
0.08
|
| Gain On Sale Of Security |
|
0.10
-74.73%
|
0.38
-75.63%
|
1.54
+3314.58%
|
-0.05
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Net Income From Continuing And Discontinued Operation |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Net Income Continuous Operations |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Normalized Income |
|
-7.33
-107.45%
|
-3.53
+80.86%
|
-18.45
+48.78%
|
-36.02
|
| Net Income Common Stockholders |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Diluted EPS |
|
-0.49
+41.67%
|
-0.84
+87.33%
|
-6.63
+60.18%
|
-16.65
|
| Basic EPS |
|
-0.49
+41.67%
|
-0.84
+87.33%
|
-6.63
+60.18%
|
-16.65
|
| Basic Average Shares |
|
12.35
+228.50%
|
3.76
+46.22%
|
2.57
+18.66%
|
2.17
|
| Diluted Average Shares |
|
12.35
+228.50%
|
3.76
+46.22%
|
2.57
+18.66%
|
2.17
|
| Diluted NI Availto Com Stockholders |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Gain On Sale Of PPE |
|
0.00
-97.37%
|
0.04
-86.81%
|
0.29
|
—
|
| Total Other Finance Cost |
|
-0.15
|
—
|
—
|
—
|
| Line Item | Trend | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Assets |
|
21.12
|
—
|
| Current Assets |
|
20.13
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
19.21
|
—
|
| Cash And Cash Equivalents |
|
19.21
|
—
|
| Receivables |
|
—
|
—
|
| Accounts Receivable |
|
—
|
—
|
| Other Receivables |
|
—
|
—
|
| Prepaid Assets |
|
0.09
-24.39%
|
0.12
|
| Restricted Cash |
|
0.26
|
—
|
| Other Current Assets |
|
0.57
|
—
|
| Total Non Current Assets |
|
0.99
|
—
|
| Net PPE |
|
0.99
|
—
|
| Gross PPE |
|
1.17
|
—
|
| Accumulated Depreciation |
|
-0.18
|
—
|
| Properties |
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
0.04
|
—
|
| Construction In Progress |
|
0.00
-100.00%
|
0.02
|
| Other Properties |
|
1.08
-35.34%
|
1.66
|
| Leases |
|
0.06
|
—
|
| Total Liabilities Net Minority Interest |
|
31.78
|
—
|
| Current Liabilities |
|
23.09
|
—
|
| Payables And Accrued Expenses |
|
5.82
|
—
|
| Payables |
|
3.02
|
—
|
| Accounts Payable |
|
3.02
|
—
|
| Current Accrued Expenses |
|
2.80
|
—
|
| Current Debt And Capital Lease Obligation |
|
4.69
|
—
|
| Current Debt |
|
3.98
|
—
|
| Other Current Borrowings |
|
3.98
|
—
|
| Current Capital Lease Obligation |
|
0.71
|
—
|
| Current Deferred Liabilities |
|
12.54
|
—
|
| Current Deferred Revenue |
|
12.54
|
—
|
| Other Current Liabilities |
|
0.04
-98.79%
|
3.72
|
| Total Non Current Liabilities Net Minority Interest |
|
8.69
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
8.69
|
—
|
| Long Term Debt |
|
8.56
-28.67%
|
12.00
|
| Long Term Capital Lease Obligation |
|
0.14
|
—
|
| Stockholders Equity |
|
-10.66
|
—
|
| Common Stock Equity |
|
-10.66
|
—
|
| Capital Stock |
|
0.02
|
—
|
| Common Stock |
|
0.02
|
—
|
| Preferred Stock |
|
0.00
|
—
|
| Share Issued |
|
2.17
-0.48%
|
2.18
|
| Ordinary Shares Number |
|
2.17
+0.00%
|
2.17
|
| Treasury Shares Number |
|
0.00
-100.00%
|
0.01
|
| Additional Paid In Capital |
|
263.71
|
—
|
| Retained Earnings |
|
-274.39
|
—
|
| Treasury Stock |
|
0.00
-100.00%
|
2.19
|
| Total Equity Gross Minority Interest |
|
-10.66
|
—
|
| Total Capitalization |
|
-2.10
|
—
|
| Working Capital |
|
-2.96
|
—
|
| Invested Capital |
|
1.88
|
—
|
| Total Debt |
|
13.38
|
—
|
| Net Debt |
|
—
|
—
|
| Capital Lease Obligations |
|
0.85
|
—
|
| Net Tangible Assets |
|
-10.66
|
—
|
| Tangible Book Value |
|
-10.66
|
—
|
| Dueto Related Parties Current |
|
—
|
3.72
|
| Interest Payable |
|
0.15
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.33
-34.19%
|
-4.71
+67.12%
|
-14.34
+54.97%
|
-31.84
|
| Cash Flow From Continuing Operating Activities |
|
-6.33
-34.19%
|
-4.71
+67.12%
|
-14.34
+54.97%
|
-31.84
|
| Net Income From Continuing Operations |
|
-6.00
-90.74%
|
-3.14
+81.57%
|
-17.05
+52.71%
|
-36.06
|
| Depreciation Amortization Depletion |
|
0.00
-100.00%
|
0.16
-79.73%
|
0.81
+16.40%
|
0.69
|
| Depreciation |
|
0.00
-100.00%
|
0.16
-79.73%
|
0.81
+16.40%
|
0.69
|
| Depreciation And Amortization |
|
0.00
-100.00%
|
0.16
-79.73%
|
0.81
+16.40%
|
0.69
|
| Other Non Cash Items |
|
0.24
-47.65%
|
0.47
-4.49%
|
0.49
-9.43%
|
0.54
|
| Stock Based Compensation |
|
0.23
-56.56%
|
0.54
-72.47%
|
1.97
-34.96%
|
3.02
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.04
|
| Operating Gains Losses |
|
-1.33
-242.42%
|
-0.39
+72.11%
|
-1.40
-3200.00%
|
0.04
|
| Gain Loss On Investment Securities |
|
-0.10
+74.73%
|
-0.38
+75.63%
|
-1.54
-3528.89%
|
0.04
|
| Gain Loss On Sale Of PPE |
|
-0.00
+97.37%
|
-0.04
+86.81%
|
-0.29
|
0.00
|
| Change In Working Capital |
|
0.52
+122.07%
|
-2.36
-379.15%
|
0.84
+815.25%
|
-0.12
|
| Change In Receivables |
|
2.36
+200.00%
|
-2.36
|
0.00
|
—
|
| Changes In Account Receivables |
|
2.36
+200.00%
|
-2.36
|
0.00
|
—
|
| Change In Prepaid Assets |
|
-0.34
-748.08%
|
0.05
-88.87%
|
0.47
+85.32%
|
0.25
|
| Change In Payables And Accrued Expense |
|
-1.86
-521.09%
|
0.44
-59.50%
|
1.09
+346.31%
|
0.24
|
| Change In Accrued Expense |
|
0.78
-2.27%
|
0.79
+149.94%
|
-1.59
-13.82%
|
-1.40
|
| Change In Payable |
|
-2.63
-645.89%
|
-0.35
-113.18%
|
2.68
+63.25%
|
1.64
|
| Change In Account Payable |
|
-2.63
-645.89%
|
-0.35
-113.18%
|
2.68
+63.25%
|
1.64
|
| Change In Other Working Capital |
|
0.36
+200.00%
|
-0.36
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.00
+96.95%
|
-0.13
+81.60%
|
-0.71
-15.96%
|
-0.61
|
| Investing Cash Flow |
|
0.00
-97.37%
|
0.04
-87.70%
|
0.31
+568.18%
|
-0.07
|
| Cash Flow From Continuing Investing Activities |
|
0.00
-97.37%
|
0.04
-87.70%
|
0.31
+568.18%
|
-0.07
|
| Net PPE Purchase And Sale |
|
0.00
-97.37%
|
0.04
-87.70%
|
0.31
+568.18%
|
-0.07
|
| Purchase Of PPE |
|
—
|
—
|
—
|
-0.07
|
| Sale Of PPE |
|
0.00
-97.37%
|
0.04
-87.70%
|
0.31
|
—
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.07
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
11.00
+219.89%
|
3.44
+184.25%
|
-4.08
-146.32%
|
8.81
|
| Cash Flow From Continuing Financing Activities |
|
11.00
+219.89%
|
3.44
+184.25%
|
-4.08
-146.32%
|
8.81
|
| Net Issuance Payments Of Debt |
|
1.61
-47.35%
|
3.06
+132.53%
|
-9.40
|
0.00
|
| Issuance Of Debt |
|
2.87
-21.89%
|
3.67
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-1.25
-105.74%
|
-0.61
+93.51%
|
-9.40
|
0.00
|
| Long Term Debt Issuance |
|
2.87
-21.89%
|
3.67
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-1.25
-105.74%
|
-0.61
+93.51%
|
-9.40
|
0.00
|
| Net Long Term Debt Issuance |
|
1.61
-47.35%
|
3.06
+132.53%
|
-9.40
|
0.00
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
4.89
|
0.00
|
| Proceeds From Stock Option Exercised |
|
9.69
|
0.00
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-0.30
-178.74%
|
0.38
-11.60%
|
0.43
-95.11%
|
8.81
|
| Changes In Cash |
|
4.67
+477.63%
|
-1.24
+93.17%
|
-18.11
+21.58%
|
-23.10
|
| Beginning Cash Position |
|
0.12
-91.43%
|
1.35
-93.04%
|
19.47
-54.27%
|
42.57
|
| End Cash Position |
|
4.79
+4030.17%
|
0.12
-91.43%
|
1.35
-93.04%
|
19.47
|
| Free Cash Flow |
|
-6.33
-34.19%
|
-4.71
+67.12%
|
-14.34
+55.06%
|
-31.91
|
| Interest Paid Supplemental Data |
|
0.03
-82.01%
|
0.14
-85.95%
|
0.99
-27.55%
|
1.36
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Amortization Of Securities |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
4.89
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
4.89
|
0.00
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-08 View
- 42026-05-08 View
- 42026-05-08 View
- 10-Q2026-05-05 View
- 8-K2026-05-01 View
- 10-K2026-03-17 View
- 8-K2025-08-12 View
- 42025-01-28 View
- 42025-01-28 View
- 42025-01-28 View
- 42025-01-28 View
- 42024-10-17 View
- 42024-10-17 View
- 42024-10-17 View
- 8-K2024-10-17 View
- 42024-10-17 View
- 8-K2024-07-16 View
- 8-K2024-03-29 View
- 8-K2024-03-14 View
- 42024-01-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|